At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 124 enrolled
Drug / intervention
BIA 5-1058 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomised, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058, in Healthy Male Volunteers
In Brief
A Phase 1 clinical trial evaluating BIA 5-1058 and Placebo for Hypertension and Chronic Heart Failure. Completed, enrolled 124 participants across 1 site.
Detailed Summary
The purpose of this study is to to assess the safety and tolerability of BIA 5 1058 after single and multiple oral doses
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension and Chronic Heart Failure
CountriesNetherlands
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
Primary CompletionJan 2012
First PostedJun 2014
TodayJul 2026
First PostedJun 2, 2014
Enrollment StartMar 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.1 years ago
Interventions
BIA 5-1058drug
oral administration
Placebodrug
oral administration